Treatment of various BRAF-mutated melanoma cell lines with the BRAF inhibitor dabrafenib (GSE98314) reduced the expression of EZH2 and PLK1 in a comparable manner (Figure 5F). The gene discussed is BRAF; the disease is melanoma.